NPJ Breast CancerPub Date : 2026-07-02DOI: 10.1038/s41523-026-00973-6
William S O Symmans, Kevin Tran, Chunxiao Fu, Hongxia Sun, Rebekah Gould, Lajos Pusztai, Tari King, Roberto Salgado, Vicente Valero, W Fraser Symmans, Eleni Andreopoulou
{"title":"Stage-related transcriptional changes in HR-positive/HER2-negative breast cancer.","authors":"William S O Symmans, Kevin Tran, Chunxiao Fu, Hongxia Sun, Rebekah Gould, Lajos Pusztai, Tari King, Roberto Salgado, Vicente Valero, W Fraser Symmans, Eleni Andreopoulou","doi":"10.1038/s41523-026-00973-6","DOIUrl":"https://doi.org/10.1038/s41523-026-00973-6","url":null,"abstract":"<p><p>It is important to understand how the biology of breast cancer might differ with the burden of disease. Analyzing the expression of cancer-relevant genes with increasing diagnostic stage can provide insight into the changing biology of breast cancer and may also be clinically useful. Here, we evaluated the transcriptional activity according to the stage of breast cancer (American Joint Committee on Cancer, AJCC Stage I to IV) from 1152 patients with hormone receptor-positive HER2-negative breast cancer. Fresh tumor samples were prospectively collected for clinical-translational research with transcriptional profiling. Most transcriptional signatures remained consistent across stage categories, but the significant changes associated with increasing stage were attributed to endocrine escape, decreasing differentiation, increased complexity of signal transduction, and a few metabolic changes. The clinical relevance and implications of these findings are discussed. The expression data from these high-quality samples are a new publicly available resource for researchers.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148376466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ Breast CancerPub Date : 2026-07-01DOI: 10.1038/s41523-026-01002-2
Shiliang Zhang, Katelyn J Queen, Niharika Duggirala, Eric Yang, Marla Lipsyc-Sharf, Jennifer Racz, John Bennett, Kaden Hong, Yashila Suresh, Charlotte Hamilton, Meghana Pitta, Nicole Chien, Emily La, Christy A Russell, Aditya Bardia, Nimmi S Kapoor
{"title":"Identifying the window of aggressive postpartum breast cancer based on the 21-gene Oncotype DX® test in women with HR+, HER2-negative breast cancer.","authors":"Shiliang Zhang, Katelyn J Queen, Niharika Duggirala, Eric Yang, Marla Lipsyc-Sharf, Jennifer Racz, John Bennett, Kaden Hong, Yashila Suresh, Charlotte Hamilton, Meghana Pitta, Nicole Chien, Emily La, Christy A Russell, Aditya Bardia, Nimmi S Kapoor","doi":"10.1038/s41523-026-01002-2","DOIUrl":"https://doi.org/10.1038/s41523-026-01002-2","url":null,"abstract":"<p><p>Postpartum breast cancer (PPBC) is associated with worse outcomes in young women with breast cancer and demonstrates distinct transcriptomic features, yet a temporal definition based on gene expression has not been established. We conducted a single-institution retrospective cohort study to evaluate the impact of postpartum status on the 21-gene Oncotype DX Recurrence Score® (RS) in hormone receptor-positive, HER2-negative young women with breast cancer. Among 385 patients, 153 were nulliparous, 62 were more than 10 years postpartum, and 170 were within 10 years postpartum. Diagnosis within one year of childbirth was associated with a 13.2-point higher RS compared with nulliparous patients (p < 0.001). Defining PPBC as within 3 years postpartum was associated with increased odds of RS category shift (OR 2.83, p = 0.001). In the context of contemporary adjuvant treatment, with patients diagnosed within three years postpartum more likely to receive chemotherapy, ovarian function suppression, and CDK4/6 inhibitors, differences in IDFS associated with time since last childbirth did not result in significantly worse IDFS within the follow-up period (89.0% in patients with PPBC up to 3 years vs. 93.7% in all other patients p = 0.39). These findings indicate that tumors diagnosed within the first year postpartum have significantly elevated RS, and that the period of most aggressive PPBC, as reflected by gene expression profiles, may arise in the more recently postpartum period, in the first 0-3 years postpartum.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148369281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ Breast CancerPub Date : 2026-07-01DOI: 10.1038/s41523-026-00999-w
Dusan Rasic, Sandra Sinius Pouplier, Maj-Britt Jensen, Bent Ejlertsen, Roberto Salgado, Pekka Ruusuvuori, Johan Hartman, Mattias Rantalainen, Anne-Vibeke Lænkholm
{"title":"AI-assisted image analysis of tumor-infiltrating lymphocytes as a prognostic marker in chemotherapy-naïve luminal breast cancer.","authors":"Dusan Rasic, Sandra Sinius Pouplier, Maj-Britt Jensen, Bent Ejlertsen, Roberto Salgado, Pekka Ruusuvuori, Johan Hartman, Mattias Rantalainen, Anne-Vibeke Lænkholm","doi":"10.1038/s41523-026-00999-w","DOIUrl":"10.1038/s41523-026-00999-w","url":null,"abstract":"<p><p>In triple-negative and HER2-positive breast cancer, tumor-infiltrating lymphocytes (TILs) are established predictive and prognostic biomarkers, but their role in luminal subtypes remains unclear. We investigated the prognostic significance of TILs using AI-based image analysis in 2298 luminal breast cancers from the DBCG99c cohort, classified by PAM50. Stromal (sTIL) and intraepithelial (iTIL) densities were quantified automatically using a commercial platform. Higher stromal TIL infiltration was associated with improved overall survival, particularly within the first 5 years (heterogeneity p = 0.01). In multivariable models, higher sTILs independently predicted lower risk of distant or any recurrence (sHR = 0.95, 95% CI 0.91-0.99) and improved survival (HR = 0.91, 95% CI 0.85-0.97 early; HR = 0.99, 95% CI 0.97-1.00 late). Intraepithelial TILs were not prognostic. No significant interactions were observed by molecular subtype, nodal status, or grade, although a nonsignificant trend toward stronger iTIL effects appeared in luminal B tumors. AI-based TIL quantification thus provides independent prognostic information in high-risk luminal breast cancer.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13615976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148369341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ Breast CancerPub Date : 2026-06-30DOI: 10.1038/s41523-026-01003-1
B Aldrige Allister, Winfried Hofmann, Jonathan L Lühmann, Björn Sander, Lena Wendeburg, Gunnar Schmidt, Bernd Auber, Susanne Morlot, Hannah Wallaschek, Nataliya di Donato, Brigitte Schlegelberger, Monika M Golas, Doris Steinemann
{"title":"Multi-omics analysis in suspected hereditary breast and ovarian cancer cases reveals novel candidate susceptibility factors.","authors":"B Aldrige Allister, Winfried Hofmann, Jonathan L Lühmann, Björn Sander, Lena Wendeburg, Gunnar Schmidt, Bernd Auber, Susanne Morlot, Hannah Wallaschek, Nataliya di Donato, Brigitte Schlegelberger, Monika M Golas, Doris Steinemann","doi":"10.1038/s41523-026-01003-1","DOIUrl":"10.1038/s41523-026-01003-1","url":null,"abstract":"<p><p>More than 80% of patients who meet clinical criteria for hereditary breast and ovarian cancer (HBOC) do not show pathogenic variants in BRCA1, BRCA2, and other diagnostically consented core genes. We hypothesized that variants in further DNA repair genes, cryptic genomic alterations, or polygenic factors may explain HBOC risk. We studied 134 patients with breast cancer and/or ovarian cancer by the use of whole genome sequencing (WGS), whole transcriptome sequencing (WTS), optical genome mapping (OGM), and mobile element analysis. We identified (likely) pathogenic variants in DNA repair genes in 18 patients, including several RECQ helicase and other DNA repair genes, an intragenic FANCM deletion, and six rare mobile element insertions (MEIs) in DNA repair genes. Incorporating PRS306 shifted estimated lifetime breast cancer risk by ≥5 percentage points in a subset of women (n = 75), including carriers of rare variants in DNA repair genes, resulting in both upward and downward risk estimation.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"12 1","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13319475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148361856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Flavonoid-rich foods, genetic risk, and female breast cancer risk: a prospective cohort study.","authors":"Rui Yang, Yi-Lin Xu, Ying Wang, Wei-Yi Xing, Wen-Rui Zheng, Jia-Xin Liu, Bang-Quan Liu, Jia-Cheng Liu, Chao Ni, Ting-Ting Gong, Shan-Yan Gao, Qi-Jun Wu","doi":"10.1038/s41523-026-00989-y","DOIUrl":"10.1038/s41523-026-00989-y","url":null,"abstract":"<p><p>The Flavodiet Score (FDS) represents flavonoid-rich food intake, but its association with breast cancer risk and whether genetic risk modifies this association remain unclear. We analyzed data from 93,271 females in the UK Biobank with a median follow-up of 11.8 years. Associations were examined using delayed-entry Cox proportional hazards regression models. The polygenic risk score (PRS) for breast cancer was constructed based on 168 single nucleotide polymorphisms. Results showed that females in the highest FDS quintile had a 15% reduced risk compared with those in the lowest quintile. Higher intakes of specific flavonoid subclasses (such as flavanones and proanthocyanidins) and of flavonoid-rich foods (including oranges and apples) were also associated with reduced breast cancer risk. Furthermore, the association between FDS and breast cancer risk did not vary significantly according to menopausal status. Notably, among females with high PRS, those in the highest quintile of FDS showed a significantly reduced breast cancer risk. In conclusion, adherence to a flavonoid-rich diet may reduce breast cancer risk, providing valuable guidance for future intervention studies and public health strategies.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148361830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ Breast CancerPub Date : 2026-06-27DOI: 10.1038/s41523-026-01001-3
Wanbing Wang, Congyu Zhang, Benyam Muluneh, Quefeng Li, Jim H Hughes, Lynne I Wagner, William A Wood, Ethan Basch, Jiawei Zhou
{"title":"Patient-reported outcomes as early indicators of recurrence, disease progression, and survival via machine learning in breast cancer.","authors":"Wanbing Wang, Congyu Zhang, Benyam Muluneh, Quefeng Li, Jim H Hughes, Lynne I Wagner, William A Wood, Ethan Basch, Jiawei Zhou","doi":"10.1038/s41523-026-01001-3","DOIUrl":"https://doi.org/10.1038/s41523-026-01001-3","url":null,"abstract":"<p><p>Patient-reported outcomes (PROs) offer a non-invasive, low-cost way to capture patients' symptoms, functioning, and quality of life. Yet, their potential as early indicators of tumor size, recurrence/disease progression, and survival remains unclear. We retrospectively analyzed 445,239 longitudinal PRO entries from 2738 patients with breast cancer, pooled from four clinical trials, including both early- and late-stage disease, covering 15 PRO measures. Among patients with radiographically confirmed recurrence or disease progression, 89.2% experienced at least one PRO deterioration prior to relapse detection (85 vs. 706 days), indicating that PROs often worsen before imaging-confirmed relapse. Cox proportional hazards models showed that PRO deterioration was significantly associated with metastatic sites, tumor size, and survival. Appetite loss was most strongly correlated with tumor size, while pain and diarrhea were the most prognostic symptoms for overall survival (OS) and progression-free survival (PFS). Gradient boosting models further showed that combining PRO deterioration times across all subscales with PFS best predicted OS, correctly classifying survival outcomes in over 93% of cases (AUC - ROC = 0.932), outperforming models using PROs alone (AUC - ROC = 0.806) or PFS alone (AUC - ROC = 0.88). This indicates that integrating PROs with PFS enhances the prediction of OS, providing a more powerful approach than using either measure alone. These findings suggest that PROs can serve as early, complementary predictors of recurrence, disease progression, and survival, supporting their use as patient-centered biomarkers in breast cancer management. Our findings align with FDA and EMA efforts to integrate PROs into oncology endpoints, supporting more patient-centered regulatory evaluation.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148352086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ Breast CancerPub Date : 2026-06-27DOI: 10.1038/s41523-026-00987-0
Ayça N Mogol, Jin Young Yoo, Alicia Arredondo Eve, Mahima Goel, David J Dutton, Claire P Schane, Audrey Lam, Debapriya Dutta, Betsy Barnick, Eda D Erdogan, Erik R Nelson, Maria Grosse-Perdekamp, Zeynep Madak-Erdogan
{"title":"ACSS2-mediated metabolic-epigenetic crosstalk drives Fulvestrant resistance and represents a novel therapeutic target.","authors":"Ayça N Mogol, Jin Young Yoo, Alicia Arredondo Eve, Mahima Goel, David J Dutton, Claire P Schane, Audrey Lam, Debapriya Dutta, Betsy Barnick, Eda D Erdogan, Erik R Nelson, Maria Grosse-Perdekamp, Zeynep Madak-Erdogan","doi":"10.1038/s41523-026-00987-0","DOIUrl":"10.1038/s41523-026-00987-0","url":null,"abstract":"<p><p>Endocrine therapies targeting estrogen receptor alpha (ERα), expressed in ~70% of breast cancers, remain the standard of care for ER+ disease. However, 30-40% of patients experience recurrence and metastasis, with 5-year survival rates of only 31.9%. Using the Carle Foundation Hospital cohort and liver metastatic patient-derived xenograft models, we identified upregulated lipid metabolism and acetyl-CoA production as metabolic vulnerabilities. We demonstrate that combining Fulvestrant (Fulv) with an inhibitor of Acyl-CoA Synthetase Short Chain Family Member 2 (ACSS2) synergistically reduces metastatic breast cancer cell viability. Through isotope tracing, CUT&RUN sequencing, immunofluorescence, western blot, and RNA sequencing, we show that Fulv increases ACSS2 expression and acetate utilization, redirecting acetate flux from the TCA cycle toward fatty acid synthesis. Nuclear ACSS2 chromatin occupancy increases with Fulv treatment, expanding ERα/ACSS2/H3K27ac co-occupancy at tumor progression genes, an effect abolished by ACSS2 inhibition. RNA sequencing revealed that ACSS2 inhibition suppresses Fulv-induced metabolic and oncogenic transcriptional programs. In a therapy-resistant xenograft model, combination treatment reduced Fulv-dependent metastatic burden. These findings establish ACSS2 as a driver of endocrine resistance through nuclear acetyl-CoA provision for epigenetic reprogramming, representing a novel therapeutic target in metastatic breast cancer.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13677737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148339580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prospective observational study of atezolizumab plus nab-paclitaxel in patients with metastatic triple-negative breast cancer: JBCRG-C08/ATTRIBUTE.","authors":"Tatsunori Shimoi, Nobuhiro Shibata, Masahiro Kitada, Michiko Tsuneizumi, Mitsugu Yamamoto, Yukinori Ozaki, Yumi Fujimoto, Sayuri Akiyoshi, Naoki Hashimoto, Miki Yamaguchi, Yutaka Yamamoto, Norikazu Masuda, Hiroshi Tada, Takashi Yamanaka, Yuichiro Kikawa, Tetsuhiko Taira, Shizuka Nakagawa, Taizo Takahashi, Mari S Oba, Naoki Niikura","doi":"10.1038/s41523-026-00997-y","DOIUrl":"10.1038/s41523-026-00997-y","url":null,"abstract":"<p><p>The JBCRG-C08/ATTRIBUTE (UMIN000041747) study assessed atezolizumab plus nab-paclitaxel's safety and effectiveness in a metastatic triple-negative breast cancer population, including IMpassion130-ineligible patients. The primary outcome was incidence of investigator-assessed adverse events (AEs). Safety and full analysis populations included 149 and 148 patients, respectively; 4.0% of the full analysis population had Eastern Cooperative Oncology Group performance status ≥2 and 7.4% had a history/comorbidity of autoimmune disease (AID) at baseline. AEs occurred in 96.6% of the safety analysis population; serious AEs (SAEs), in 16.8%; and immune-related AEs (irAEs), in 30.9%. irAE incidence was 45.5% in patients with a history/comorbidity of AID. Notable SAEs included pneumonitis (3.4%), diarrhoea, pyrexia, adrenal insufficiency and cardiac failure (1.3% each). Two cases of Grade 5 pneumonitis occurred. Regarding effectiveness, median progression-free survival was 5.6 months (95% confidence interval, 4.2-6.7). This first analysis found no new safety concerns with atezolizumab combination therapy, although patients with AID require careful monitoring.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13672298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148339526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ Breast CancerPub Date : 2026-06-26DOI: 10.1038/s41523-026-00971-8
Hope S Rugo, David W Cescon, Peter Schmid, Zbigniew Nowecki, Seock-Ah Im, Mastura Md Yusof, Carlos Gallardo, Hiroji Iwata, Oleg Lipatov, Felipe Cruz, Carlos Henrique Barrios, Roberto Hegg, Sherene Loi, Maria Gion, Marco Torregroza Otero, Péter Árkosy, Rafal Tarnawski, Lili Yao, Jaime Mejia, Wilbur Pan, Javier Cortés
{"title":"Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events.","authors":"Hope S Rugo, David W Cescon, Peter Schmid, Zbigniew Nowecki, Seock-Ah Im, Mastura Md Yusof, Carlos Gallardo, Hiroji Iwata, Oleg Lipatov, Felipe Cruz, Carlos Henrique Barrios, Roberto Hegg, Sherene Loi, Maria Gion, Marco Torregroza Otero, Péter Árkosy, Rafal Tarnawski, Lili Yao, Jaime Mejia, Wilbur Pan, Javier Cortés","doi":"10.1038/s41523-026-00971-8","DOIUrl":"10.1038/s41523-026-00971-8","url":null,"abstract":"<p><p>Pembrolizumab plus chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) versus chemotherapy in the phase 3 randomized KEYNOTE-355 study in participants with previously untreated, advanced triple-negative breast cancer (TNBC) with PD-L1 combined positive score (CPS) ≥ 10. Among participants with clinical benefit from pembrolizumab plus chemotherapy, discontinuation of chemotherapy before pembrolizumab for any reason was associated with similar median PFS and OS to that in the overall population. Additionally, we further characterized immune-mediated adverse events (AEs) in KEYNOTE-355. Most immune-mediated AEs were manageable with treatment interruption and supportive care. In participants treated with pembrolizumab plus chemotherapy with immune-mediated AEs, there appeared to be numerical improvement in efficacy. This analysis provides additional information on the use of pembrolizumab plus chemotherapy as standard-of-care therapy in patients with previously untreated, advanced TNBC with PD-L1 CPS ≥ 10. This trial is registered at ClinicalTrials.gov (NCT02819518; registration date, June 28, 2016).</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13677730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148339549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NPJ Breast CancerPub Date : 2026-06-25DOI: 10.1038/s41523-026-00996-z
Reine Abou Zeidane, Benjamin Hauk, Samuel Lichtman-Mikol, Courtney Pisano, Yilun Sun, Priyanka Shailendra Rana, Citlally Lopez-Flores, Breanna N McBean, Kassidy M Jungles, Trisha Lal, Nihit Mehta, Philip Bomeisl, Amanda L Amin, Alberto J Montero, Janice Lyons, Corey W Speers
{"title":"Prognostic consistency of oncotype DX® molecular assay across racial groups in early-stage hormone receptor-positive breast cancer.","authors":"Reine Abou Zeidane, Benjamin Hauk, Samuel Lichtman-Mikol, Courtney Pisano, Yilun Sun, Priyanka Shailendra Rana, Citlally Lopez-Flores, Breanna N McBean, Kassidy M Jungles, Trisha Lal, Nihit Mehta, Philip Bomeisl, Amanda L Amin, Alberto J Montero, Janice Lyons, Corey W Speers","doi":"10.1038/s41523-026-00996-z","DOIUrl":"10.1038/s41523-026-00996-z","url":null,"abstract":"<p><p>In this retrospective cohort study, we evaluated the consistency of prognostic outcomes provided by the Oncotype DX® assay across different racial groups among women with early-stage hormone receptor-positive (HR + ) breast cancer. Data was abstracted from the electronic medical record of 1122 patients with non-metastatic HR+ breast cancer who underwent Oncotype DX testing at University Hospitals Seidman Cancer Center between 2013 and 2023. Recurrence Score (RS) categories were defined using historical cutpoints: low(0-18), intermediate(19-30), and high(31-100). Two contemporary-cutpoint sensitivity analyses based on TAILORx and RxPONDER were also performed: binary scheme (0-25;26-100) and three-level scheme (RS 0-15;16-25;26-100). Recurrence-free survival (RFS) and overall survival (OS) were analyzed using Kaplan-Meier curves and adjusted Cox models. The cohort included 142 African American (AA) and 967 White women. Under the historical cutpoints, AA women had a higher prevalence of intermediate and high-risk RS. Despite these differences, 5-year RFS and OS were comparable. In multivariable analyses, AA race was not independently associated with RFS or OS. Sensitivity analyses using contemporary cutpoints yielded concordant findings. These findings support consistent prognostic value of Oncotype DX assay across racial groups, although further investigation into socioeconomic and clinical contributors to disparities is warranted.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13658793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148331561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
